Ignite Creation Date:
2024-05-05 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 9:58 AM
Study NCT ID:
NCT00796055
Status:
TERMINATED
Last Update Posted:
2011-11-17
First Post:
2008-11-20
Brief Title:
Study of MEDI-547 to Evaluate the Safety Tolerability and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Phase 1 Open-Label Study of MEDI-547 to Evaluate the Safety Tolerability Pharmacokinetics and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression
Status:
TERMINATED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
MI-CP177 study closed per sponsor decision
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MEDI-547
Brief Summary:
To determine the safety tolerability and the highest dose of this drug given once every 3 weeks or once every week per 21 day cycle in adult subjects with relapsed or refractory solid tumors
Detailed Description:
To determine the safety tolerability and maximum tolerated dose MTD of MEDI 547 in a dose escalation cohort for either administration schedule 1 dose every 3 weeks or 1 dose every week in adult subjects with relapsed or refractory solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None